CN105434428A - Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer - Google Patents
Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer Download PDFInfo
- Publication number
- CN105434428A CN105434428A CN201510962952.6A CN201510962952A CN105434428A CN 105434428 A CN105434428 A CN 105434428A CN 201510962952 A CN201510962952 A CN 201510962952A CN 105434428 A CN105434428 A CN 105434428A
- Authority
- CN
- China
- Prior art keywords
- volvalerelactonesb
- treatment
- volvalerelactones
- ulcer
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer for the first time. The skeleton type of Volvalerelactones B is a novel skeleton type, and treatment activity of Volvalerelactones B on dental ulcer is unexpectedly high; it is impossible to obtain any enlightenment from other compounds; substantiality is prominent; and obvious development is achieved when Volvalerelactones B is applied to treatment of dental ulcer.
Description
Technical field
The present invention relates to the novelty teabag of compound VolvalerelactonesB, particularly relate to the application of VolvalerelactonesB in preparation treatment or preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus (1975) investigates 1587 people, and prevalence is 20%.As can be seen here, oral ulcer patient is a very huge colony.The cause of disease of recurrent oral ulceration is complicated, still indefinite so far, may be relevant with the factor such as the endocrine regulation of viral infection, bacteriological infection and body, immune dysfunction.
The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because topical therapeutic toxic and side effects is lower, the people therefore obtaining people can.Although the buccal tablets that the local that occurs in recent years uses carries, easy to use, mouthfeel and compliance better, as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields in sterilization, antiinflammatory, pain relieving etc.
The compound VolvalerelactonesB that the present invention relates to is one and delivers (Peng-ChengWang in 2011, etal., VolvalerelactonesAandB, TwoNewSesquiterpenoidLactoneswithanUnprecedentedSkeleton fromValerianaofficinalisvar.latifolia.OrganicLetters, 2011, 13 (12), 3036 – 3039.) noval chemical compound, this compound has brand-new framework types (Peng-ChengWang, etal., VolvalerelactonesAandB, TwoNewSesquiterpenoidLactoneswithanUnprecedentedSkeleton fromValerianaofficinalisvar.latifolia.OrganicLetters, 2011, 13 (12), 3036 – 3039.), the purposes of the VolvalerelactonesB that the present invention relates in preparation treatment or preventing canker sore medicine is belonged to first public, owing to belonging to brand-new structure type, and its for treatment or preventing canker sore active unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, to be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report for the treatment of or preventing canker sore according in existing VolvalerelactonesB research, provide the application of VolvalerelactonesB in preparation treatment or preventing canker sore medicine.
Described compound VolvalerelactonesB structure is as shown in formula I:
The application of described VolvalerelactonesB in preparation treatment or preventing canker sore medicine, VolvalerelactonesB reduces rat ulcer area.
A kind for the treatment of or preventing canker sore medicine, be that active component interpolation adjuvant is prepared from by VolvalerelactonesB, preparation method, for getting 5 g of compound VolvalerelactonesB, adds 195 grams, dextrin, and mixing, Conventional compression makes 1000.
A kind for the treatment of or preventing canker sore medicine, be that active component adds adjuvant and is prepared from by VolvalerelactonesB, preparation method, for getting 5 g of compound VolvalerelactonesB, adds starch 195 grams, mixing, encapsulatedly makes 1000.
The purposes of the VolvalerelactonesB that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public, because framework types belongs to brand-new framework types, and its treatment or preventing canker sore active unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, to be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.
Detailed description of the invention
The preparation method of compound VolvalerelactonesB involved in the present invention is see document (Peng-ChengWang, etal., VolvalerelactonesAandB, TwoNewSesquiterpenoidLactoneswithanUnprecedentedSkeleton fromValerianaofficinalisvar.latifolia.OrganicLetters, 2011,13 (12), 3036 – 3039.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound VolvalerelactonesB tablet involved in the present invention:
Get 5 g of compound VolvalerelactonesB and add 195 grams, dextrin, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound VolvalerelactonesB capsule involved in the present invention:
Get 5 g of compound VolvalerelactonesB and add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
The experimental study of test example 1:VolvalerelactonesB anti-oral ulcer
1, test objective: manufacture Oral ulcer model with phenol, gives the VolvalerelactonesB of Oral ulcer model rat certain number of times every day, and whether observe VolvalerelactonesB has the effect reducing ulcer.
2, test medicine and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol
Animal: Wistar rat, male, body weight 240 ~ 280g
3, test method
Get rat 50, male, body weight 240 ~ 280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, after anesthesia, plastic dropper (internal diameter: the 3mm) lower end of 90% phenol cotton balls being flat on rats with left bicker is about on the cheek film at 1mm place, calcination 30min, namely sees the white infringement of this place about 3mm.Divide into groups immediately after 24 hours, often organize 10, divide 5 groups, i.e. model group (adjuvant 4 times/day, not drug containing); VolvalerelactonesB high dose group (4 times/day, 0.5mg/ time); Dosage (4 times/day, 0.1mg/ time) in VolvalerelactonesB; VolvalerelactonesB low dose group (4 times/day, 0.02mg/ time); Positive controls: cydiodine group (4 times/day, 0.5mg/ time).VolvalerelactonesB and cydiodine buccal tablet pulverize before use, administration is degree of being with flap coverage.Successive administration 5 days, after the front and each administration of administration, next day observes ulcer area size (diameter in ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer), and first administration is recorded as 1,2,3,4,5,6 day respectively to last administration.Ulcer area size t checks, and ulcer healing rate X2 checks.
4, result of the test
Ulcer area compares (table 1): VolvalerelactonesB high dose group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; Cydiodine group compares with model group, within the 3rd day, plays test from administration
Terminate, corresponding every day compares significant difference; In VolvalerelactonesB, dosage group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; VolvalerelactonesB low dose group compares with model group, within the 5th day, plays off-test from administration, and corresponding every day compares significant difference; In VolvalerelactonesB, dosage group compares with cydiodine group, within the 1st day, plays off-test from administration, and corresponding every day compares significant difference.
Table 1 is on the impact of rat ulcer area
Note: compare with model group, * p<0.05, * p<0.01.
Healing rate (table 2): model group and VolvalerelactonesB low dose group play off-test on the 1st day from administration, and ulcer does not heal; And VolvalerelactonesB high dose group was from administration the 4th day, just there is ulcer healing, to off-test, reach 90%; Cydiodine group, from administration the 4th day, has ulcer healing, to off-test, reaches 60%; In VolvalerelactonesB, dosage group was from administration the 5th day, had ulcer healing, to off-test, reached 40%.
Table 2 is on the impact of rat ulcer healing time
Note: compare with model group, * p<0.05, * p<0.01.
5, conclusion
VolvalerelactonesB has the effect obviously promoting oral ulcer healing.
Claims (4)
- The application of 1.VolvalerelactonesB in treatment or preventing canker sore medicine, described compound VolvalerelactonesB structure is as shown in formula I:
- 2. the application of VolvalerelactonesB in treatment or preventing canker sore medicine as claimed in claim 1, is characterized in that VolvalerelactonesB reduces rat ulcer area.
- 3. a treatment or preventing canker sore medicine, it is characterized in that by VolvalerelactonesB described in claim 1 being that active component interpolation adjuvant is prepared from, preparation method, for getting 5 g of compound VolvalerelactonesB, adds 195 grams, dextrin, mixing, Conventional compression makes 1000.
- 4. a treatment or preventing canker sore medicine, it is characterized in that by VolvalerelactonesB described in claim 1 being that active component interpolation adjuvant is prepared from, preparation method, for getting 5 g of compound VolvalerelactonesB, adds starch 195 grams, mixing, encapsulatedly makes 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510962952.6A CN105434428A (en) | 2015-12-18 | 2015-12-18 | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510962952.6A CN105434428A (en) | 2015-12-18 | 2015-12-18 | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105434428A true CN105434428A (en) | 2016-03-30 |
Family
ID=55545363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510962952.6A Pending CN105434428A (en) | 2015-12-18 | 2015-12-18 | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434428A (en) |
-
2015
- 2015-12-18 CN CN201510962952.6A patent/CN105434428A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102805746B (en) | A kind of act on respiratory system disease compound chemical medicine and preparation technology and application | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN105434428A (en) | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN105412109A (en) | Application of Biscarpamontamine B in preparing drugs for treating or preventing dental ulcers | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN105147676A (en) | Medicine for preventing or treating dental ulcer | |
| CN105287543A (en) | Application of strynuxlines B to prepare medicines treating or preventing oral ulcer | |
| CN106491621A (en) | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN106619604A (en) | Medicine for treating or preventing dental ulcer, and application of medicine | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN107837278A (en) | Orientin is preparing the application in treating or preventing stomatocace medicine | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160330 |